Back to Authors

Tobin, W Oliver

0000-0002-8141-2394

Mayo Clinic

Department of Neurology, Mayo Clinic, Rochester, MN.

Citations 47

Profile of reticulated platelets in the early, subacute and late phases after transient ischemic attack or ischemic stroke

Platelets | December 21, 2020 | Volume: 33 | Issue: 1 | Pages: 89-97

10.1080/09537104.2020.1850670 | PMID 33347340

Teaching NeuroImages: Brain and Skin Involvement in Erdheim-Chester Disease

Neurology | November 10, 2020 | Volume: 96 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000011159 | PMID 33168700

Low-dose vemurafenib monotherapy in BRAFV600E-mutated Erdheim-Chester disease

Leukemia & Lymphoma | July 1, 2020 | Volume: 61 | Issue: 11 | Pages: 2733-2737

10.1080/10428194.2020.1783447 | PMID 32608295

Pathological findings in central nervous system demyelination associated with infliximab

Multiple Sclerosis Journal | December 17, 2019 | Volume: 26 | Issue: 9 | Pages: 1124-1129

10.1177/1352458519894710 | PMID 31845616

Background: Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders. Objective: To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS). Methods: We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical–radiographic–neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described. Results and conclusion: Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.
Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms

Blood | January 29, 2019 | Volume: 133 | Issue: 14 | Pages: 1607-1610

10.1182/blood-2018-12-893917 | PMID 30696619

Growing the phenotype of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) in children

Developmental Medicine & Child Neurology | September 24, 2018 | Volume: 61 | Issue: 4 | Pages: 391-392

10.1111/dmcn.14043 | PMID 30246371

This commentary is on the case series by Sa et al. on pages 490–496 of this issue.
Reply to: “Crowell et al. Idiopathic Central Nervous System Inflammatory Disease in the Setting of HLA-B27 Uveitis”

Ocular Immunology and Inflammation | June 30, 2018 | Volume: 27 | Issue: 6 | Pages: 918-919

10.1080/09273948.2018.1484497 | PMID 29958047